Slide 1: Investor Presentation June 2015
Investor Presenta,on June 2015 For personal use only Global Momentum Rob Phillips PhD(med), MPhil(med), FASE, DMU(cardiol) Associate Professor, Critical Care Research Group, School of Medicine, The University of Queensland CEO 1 The Measure of Life
Slide 2: Disclaimer
Disclaimer For personal use only This presenta,on is intended to provide a general outline only and is not intended to be a defini,ve statement on the subject ma9er. The informa,on in this presenta,on, whether wri9en or verbal, has been prepared without taking into account the commercial, financial or
Slide 3: For personal use only
For personal use only 3 http://news.bbc.co.uk/2/hi/uk_news/england/nottinghamshire/8525901.stm
Slide 4: Uscom Vision
Uscom Vision For personal use only Company of the Year, 2014 Johnson & Johnson Innova9on Industry Excellence Awards “A milestone driven Australian bio device company, with real products, real revenue, and real growth which is approaching profitability…” 4
Slide 5: Current Business
Current Business For personal use only § Premium noninvasive cardiovascular monitoring devices § Addressing the growing threat of superbugs § Validated, clinically accepted, cost and life saving devices § Patent protected with regulatory approvals § Rapidly growing revenues in major markets and
Slide 6: Current Products
Current Products For personal use only USCOM 1A BP+ Cardiac Output Monitor Blood Pressure Monitor USCOM 1A BP+ § World leading technology offering huge poten,al § Next genera,on blood pressure monitoring savings to global healthcare systems providing central and brachial BP measurement § Sold into
Slide 7: Targeting Strong Revenue Growth
Targeting Strong Revenue Growth For personal use only USCOM 1A BP+ Cardiac Output Monitor Blood Pressure Monitor USCOM 1A BP+ § US$1.3bn global market with CAGR of 7.6%* § US$1.7bn global market with CAGR of 11.5%* § Increasing unit sales globally § US$7m $1.4m pa China distribu,on agreement sig
Slide 8: Uscom Growth
Uscom Growth For personal use only Fluid, Sepsis Hypertension & & Heart Failure Vascular Health § US 1.3bn market * § US 1.7bn market * § CAGR of 7.6% * § CAGR of 11.5% * USCOM 1A Cardiac Output Monitoring + BP+ Blood Pressure Monitoring Complementary products and technology 8 * Source: MedTech
Slide 9: Growth in Distribution
Growth in Distribution For personal use only Distribution Agreements 40 34 35 30 +30% 27 25 20 +125% 15 12 10 5 0 2013 2014 2015* Further distribu9on growth through 9 investment in people * FY to date
Slide 10: Sales and Profit Trends
Under NDA Sales and Profit Trends For personal use only Quarterly Sales Annual Net Loss Revenue $0k 2011 2012 2013 2104 2015* 2016* $600k $500k -$500k $400k -$1,000k $300k -$1,500k $200k $100k -$2,000k $0k -$2,500k -$3,000k A number of key future USCOM 1A and BP+ 10 revenue drivers already in train
Slide 11: BP+ US Reimbursement
BP+ US Reimbursement For personal use only US Category 1 CPT Code recommended by AMA CPT panel * § Provides financial model for Drs to use BP+ § CPT Category 1 Code (9300X1) BP+ has US FDA clearance § Non-‐invasive calcula,on and analysis of central arterial pressure waveforms with interpreta,on
Slide 12: USCOM 1A Around the World
USCOM 1A Around the World For personal use only •• • •• •••••• • • • •• • • ••• •• •• • •• • • • • • •• • •• Over 700 USCOM units sold worldwide 12
Slide 13: Uscom Products
Uscom Products For personal use only Two products each at commercializa9on phase Global Profit Concept Product Pilot Valida,on Regulatory Revenue Distribu,on 2016 USCOM ±✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ Uscom ±✓ BP+ ✓ ✓ ✓ ✓ ✓ ✓ ✓ Turning unrecognised IP into balance sheet value 13
Slide 14: Regulatory Strategy
Regulatory Strategy For personal use only Global regulatory approvals * § Both devices are FDA, CE and TGA approved § Next step is CFDA approval for BP+ USCOM 1A BP+ FDA ✓ ✓ CE ✓ ✓ CFDA ✓ P TGA ✓ ✓ ✓ Approved P Preparation for submission 14
Slide 15: Reimbursement Strategy
Reimbursement Strategy For personal use only Head of reimbursement affairs appointed USCOM 1A Uscom BP+ MSAC (Aus) Ini,ated Background CPT (USA) Background Granted NHS (UK) Review Background ROW -‐ -‐ Timelines § USCOM 1A: Australia Aug 2015; UK Oct 15; US 2016 § BP+: Australia Nov 2015; UK Nov 2
Slide 16: Broad Patent Portfolio
Broad Patent Portfolio For personal use only Core technology patent protected, with patents running to 2024 and beyond USCOM 1A BP+ § 22 granted patents § 34 granted patents § 5 pending applica,ons § 4 registered trademarks § 2 registered trademarks IP protected in key markets 16
Slide 17: De-Risked Technology
De-Risked Technology For personal use only Featured in 400+ peer reviewed publica9ons and presenta9ons Sepsis, Heart failure, Hypertension, Fluid management, Emergency, Pediatrics, Cardiac transplantation, Electrophysiology, Emergency transport, Anesthesia, Liver transplantation, ICU, Pre-eclampsia,
Slide 18: USCOM Saving Lives
USCOM Saving Lives For personal use only § 10 Million women get pre-‐eclampsia per year § 76,000 mothers die per year (200 per day) and 500,000 unborn babies (1300 per day) § Early detec,on and treatment associated with be9er outcomes § USCOM detects pre-‐eclampsia at 5 weeks not 20 weeks as c
Slide 19: USCOM Saving Lives
USCOM Saving Lives For personal use only Na9onal ICU Study – Sepsis and sep9c shock mortality 6yr Australian Prac9ce Audit ANZICS CORE Adult database 30 25 20 15 10 BUSH protocol introduced 5 0 2006 2007 2008 2009 2010 2011 2012 Bathurst USCOM Australia Australian Rural Smith BE, Phillips RA, Madiga
Slide 20: USCOM Reducing Costs
USCOM Reducing Costs For personal use only Na9onal ICU Study 6 yr Australian Prac9ce Audit ANZICS CORE Adult database Mean Cost per Admission 2007- 2012 $60,000 $48,000 $50,000 $41,645 $40,000 $30,000 $26,273 $20,000 $10,000 $0 Australian Australian Rural BUSH Mean cost per hospitalisa,on for sepsis
Slide 21: USCOM 1A Competitive Advantage
USCOM 1A Competitive Advantage For personal use only Non- SV beat Method Manufacturer Technology Rel+Rep invasive Simple Cost Portable to beat USCOM 1A Uscom Doppler ✓ ✓ ✓ ✓ ✓ ✓ BioZ Samsung BioImpedance ✗ ✓ ✓ ✗ ✓ ✗ NiCOM Cheetah BioReactance ✗ ✓ ✓ ✗ ✓ ✗ Nexfin Bmeye APP ✗ ✓ ✓ ✓ ✓ ✗ CardioQ Deltex D
Slide 22: BP+ Competitive Advantage
BP+ Competitive Advantage For personal use only Uscom BP+ TensioMed BPLab IEM Centron AtCor Australia Hungary Russia Germany UK Australia USD 3,950 USD 6,000 USD 7,000 USD 7,000 USD 6,300 USD 14,000 1 min 2 min 2 min 2 min 1 min 1 min Stand-alone ABP, needs computer ABP, needs computer ABP, needs co
Slide 23: Why? Independent published research
Why ? For personal use only Independent published research – BP+ most clinically applicable cBP monitor ✓ Cambridge University, Weill Cornell, University of California, Wales Heart Institute McEniery CM, Cockcroft JR, Roman MJ, Franklin SS, Wilkinson AB. Central blood pressure: current evidence and
Slide 24: Testimonials
Testimonials For personal use only “This machine is saving lives, there are no two ways about it.” Professor Brendan Smith, AnestheCst, Intensivist and Emergency Physician, N.S.W. Dept of Health, Australia “USCOM has changed the way I look at the cardiovascular status of my paCents. It’s part of the
Slide 25: Revenue Drivers
Revenue Drivers For personal use only ü USCOM 1A growth ü US BP+ Re-‐imbursement -‐ CPT category 1 code (9300X1) effecCve January 2016 ü BP+ CFDA – China sales ü USCOM 1A and BP+ sales pipeline growing (Pioneer + Europe) ü Increased distribuCon (Uscom and BP+) – increases revenue for all produ
Slide 26: Value at many levels
Uscom For personal use only Value at many levels Revenue growth ✓ Approved products ✓ Life saving clinical applicaCons ✓ Growing organisaCon ✓ Global opportuniCes ✓ 26
Slide 27: Thank You
Investor Presenta,on June 2015 For personal use only Thank You Rob Phillips PhD(med), MPhil(med), FASE, DMU(cardiol) Associate Professor, Critical Care Research Group, School of Medicine, The University of Queensland CEO 27 The Measure of Life Uscom - The measure of life